|
Apr 18
|
23andMe announces CEO’s intention to pursue a potential take-private
|
|
Apr 18
|
23andMe CEO plans to take company private
|
|
Apr 18
|
23andMe CEO Wojcicki considering taking firm private, filing shows
|
|
Apr 17
|
Can 23andMe Holding (NASDAQ:ME) Afford To Invest In Growth?
|
|
Apr 5
|
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
|
|
Mar 24
|
Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?
|
|
Mar 20
|
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
|
|
Mar 19
|
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago
|
|
Mar 6
|
23andMe Launches New Genetic Reports on Common Forms of Cancer
|
|
Mar 5
|
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
|
|
Feb 13
|
Is 23andMe Stock a Smart Buy Right Now?
|
|
Feb 9
|
23andMe Holding Third Quarter 2024 Earnings: US$0.58 loss per share (vs US$0.20 loss in 3Q 2023)
|
|
Feb 8
|
23andMe Stock Slides After DNA-Testing Company's Disappointing Results
|
|
Feb 8
|
23andMe Holding Co. (NASDAQ:ME) Q3 2024 Earnings Call Transcript
|
|
Feb 8
|
Q3 2024 23andMe Holding Co. Earnings Call
|
|
Feb 8
|
How 23AndMe Went From a $6 Billion Valuation to a Penny Stock
|
|
Feb 7
|
23andMe Mulls Possible Split, Shares Fall After Disappointing Results
|
|
Feb 7
|
Struggling 23andMe Is Exploring Splitting the DNA Company in Two
|
|
Feb 7
|
23andMe Holding Co (ME) Faces Revenue Decline and Net Loss in Q3 FY24
|
|
Feb 7
|
23andMe Reports Third Quarter Fiscal 2024 Financial Results
|